{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T03:25:24Z","timestamp":1793849124622,"version":"4.6.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.clinthera.2026.06.007","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T19:58:08Z","timestamp":1783108688000},"page":"1131-1141","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Safety of Celecoxib in Elderly Patients With Osteoarthritis: A Real-World Analysis Based on the FAERS Database"],"prefix":"10.1016","volume":"48","author":[{"given":"Enhong","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoyao","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ridong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianglei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingjun","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2026.06.007_bib0001","first-page":"1","article-title":"The influence of zinc levels on osteoarthritis: a comprehensive review","author":"Tekeo\u011flu","year":"2024","journal-title":"Nutra Res Rev"},{"key":"10.1016\/j.clinthera.2026.06.007_bib0002","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41392-023-01330-w","article-title":"Osteoarthritis: pathogenic signaling pathways and therapeutic targets","volume":"8","author":"Yao","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.clinthera.2026.06.007_bib0003","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41392-023-01330-w","article-title":"Osteoarthritis: pathogenic signaling pathways and therapeutic targets","volume":"8","author":"Yao","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.clinthera.2026.06.007_bib0004","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202400615","article-title":"Chen Nanomaterials: recent Advances in Knee Osteoarthritis Treatment","author":"Peng","year":"2024","journal-title":"Adv Healthc Mater"},{"key":"10.1016\/j.clinthera.2026.06.007_bib0005","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.joca.2024.07.014","article-title":"Osteoarthritis year in review 2024: epidemiology and therapy","volume":"32","author":"Courties","year":"2024","journal-title":"Osteoarthritis Cartilage"},{"key":"10.1016\/j.clinthera.2026.06.007_bib0006","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1557790","article-title":"Celecoxib prevents malignant progression of smoking-induced lung tumors via suppression of the COX-2\/PGE2 signaling pathway in mice","volume":"16","author":"Sakurai","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.clinthera.2026.06.007_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2025.142578","article-title":"Design, synthesis and biological evaluation of phenoxyacetic acid derivatives linked to pyrazole scaffold as PPAR-\u03b1\/\u03b3 agonists and COX-2 inhibitors with dual antidiabetic\/anti-inflammatory activities","volume":"1340","author":"Fadaly","year":"2025","journal-title":"J Mol Struct"},{"key":"10.1016\/j.clinthera.2026.06.007_bib0008","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1080\/17568919.2025.2545171","article-title":"Novel di-aryl chalcone derived pyrazole linked to methane sulfonyl pharmacophore as potent selective COX-2 inhibitors; design, synthesis, molecular modeling, in vitro and in vivo anti-inflammatory activities","volume":"17","author":"Abd El-Hameed","year":"2025","journal-title":"Future Med Chem"},{"key":"10.1016\/j.clinthera.2026.06.007_bib0009","doi-asserted-by":"crossref","DOI":"10.1002\/slct.202504601","article-title":"Pharmaceutical applications of di\/tri-aryl pyrazole derivatives: a review on recent updates","volume":"10","author":"Nemr","year":"2025","journal-title":"ChemistrySelect"},{"key":"10.1016\/j.clinthera.2026.06.007_bib0010","doi-asserted-by":"crossref","first-page":"8992","DOI":"10.1038\/s41598-025-93357-y","article-title":"The comparative efficacy of l-glutamine, celecoxib, and glucosamine sulfate in osteoarthritis management","volume":"15","author":"Hu","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.clinthera.2026.06.007_bib0011","article-title":"Overall compilation of adverse effects of non-steroidal anti-inflammatory drugs: a hypothesis-free systematic investigation using a nationwide cohort study","volume":"16","author":"Han","year":"2025","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.clinthera.2026.06.007_bib0012","doi-asserted-by":"crossref","first-page":"6359","DOI":"10.62347\/AHTO9889","article-title":"Effects of celecoxib combined with glucosamine hydrochloride in the management of knee osteoarthritis","volume":"17","author":"Cheng","year":"2025","journal-title":"Am J Transl Res"},{"key":"10.1016\/j.clinthera.2026.06.007_bib0013","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/j.1529-8019.2012.01474.x","article-title":"Acute generalized exanthematous pustulosis-like, folliculitic drug reaction pattern caused by celecoxib","volume":"24","author":"Pakdeethai","year":"2011","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.clinthera.2026.06.007_bib0014","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMoa1611593","article-title":"Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis","volume":"375","author":"Nissen","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2026.06.007_bib0015","doi-asserted-by":"crossref","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA Adverse Event Reporting System","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int J Med Sci"},{"key":"10.1016\/j.clinthera.2026.06.007_bib0016","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.jaip.2020.09.021","article-title":"Emerging causes of drug-induced anaphylaxis: a review of anaphylaxis-associated reports in the FDA adverse event reporting system (FAERS)","volume":"9","author":"Yu","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.clinthera.2026.06.007_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104398","article-title":"Safety of immune checkpoint inhibitors: an updated comprehensive disproportionality analysis and meta-analysis","volume":"200","author":"Tyagi","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.clinthera.2026.06.007_bib0018","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000104","article-title":"T-cell lymphoma secondary to checkpoint inhibitor therapy","volume":"8","author":"Anand","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.clinthera.2026.06.007_bib0019","article-title":"GLP-1 receptor agonist-associated tumor adverse events: a real-world study from 2004 to 2021 based on FAERS","volume":"13","author":"Yang","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.clinthera.2026.06.007_bib0020","doi-asserted-by":"crossref","first-page":"789","DOI":"10.2147\/CLEP.S365513","article-title":"A real-world disproportionality analysis of olaparib: data mining of the public version of FDA adverse event reporting system","volume":"14","author":"Shu","year":"2022","journal-title":"Clin Epidemiol"},{"key":"10.1016\/j.clinthera.2026.06.007_bib0021","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/andr.13533","article-title":"A real-world pharmacovigilance study of FDA adverse event reporting system events for sildenafil","volume":"12","author":"Wang","year":"2024","journal-title":"Andrology"},{"key":"10.1016\/j.clinthera.2026.06.007_bib0022","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1259908","article-title":"A pharmacovigilance study of etoposide in the FDA adverse event reporting system (FAERS) database, what does the real world say?","volume":"14","author":"Cui","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.clinthera.2026.06.007_bib0023","doi-asserted-by":"crossref","first-page":"591","DOI":"10.2165\/00002018-200427080-00010","article-title":"Using MedDRA: implications for risk management","volume":"27","author":"Brown","year":"2004","journal-title":"Drug Saf"},{"key":"10.1016\/j.clinthera.2026.06.007_bib0024","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1231320","article-title":"Risk factors for drug-related acute pancreatitis: an analysis of the FDA adverse event reporting system (FAERS)","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.clinthera.2026.06.007_bib0025","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"Bate","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2026.06.007_bib0026","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/MCG.0000000000000888","article-title":"Celecoxib-induced liver injury: analysis of published case reports and cases reported to the food and drug administration","volume":"52","author":"Mukthinuthalapati","year":"2018","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.clinthera.2026.06.007_bib0027","doi-asserted-by":"crossref","first-page":"952","DOI":"10.2174\/1381612822666161006144942","article-title":"Cardiovascular toxicity of cyclooxygenase inhibitors and promising natura l substitutes","volume":"23","author":"Bahmani","year":"2017","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.clinthera.2026.06.007_bib0028","unstructured":"DailyMed [Internet]. Bethesda (MD): National Library of Medicine (US); 2013. CELEBREX (celecoxib) capsule, prescribing information."},{"key":"10.1016\/j.clinthera.2026.06.007_bib0029","doi-asserted-by":"crossref","first-page":"107624","DOI":"10.1016\/j.pharmthera.2020.107624","article-title":"Cyclooxygenases and the cardiovascular system","volume":"217","author":"Mitchell","year":"2020","journal-title":"Pharmacol Ther"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291826002195?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291826002195?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T02:34:48Z","timestamp":1793846088000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291826002195"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":29,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S0149291826002195"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2026.06.007","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety of Celecoxib in Elderly Patients With Osteoarthritis: A Real-World Analysis Based on the FAERS Database","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2026.06.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}